-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Edited by WuXi AppTec Content Team
Today, Santhera Pharmaceuticals and ReveraGen BioPharma jointly announced the positive results of the VISION-DMD clinical 2b trial of Duchenne muscular dystrophy (DMD) investigational drug vamorolone, published in the leading journal JAMA NeurologyDMD is a rare X-chromosome-linked genetic disorder caused by mutations in the gene encoding dystrophin on the X chromosome, and therefore affects almost exclusively male patients and is one of the most common childhood neuromuscular diseases one
▲Molecular formula of Vamorolone (Image source: Fvasconcellos (talk · contribs), Public domain, via Wikimedia Commons)
The data published this time showed that vamorolone met the primary endpoint of the trial at 24 weeks